TD Asset Management
SYRE icon

TD Asset Management’s Spyre Therapeutics SYRE Stock Holding History

TD Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Sell
115,990
-21,400
-16% -$1.56M 0.01% 650
2026
Q1 		$6.93M Sell
137,390
-12,432
-8% -$469K 0.01% 730
2025
Q4 		$4.91M Buy
149,822
+77,454
+107% +$2.02M ﹤0.01% 804
2025
Q3 		$1.21M Sell
72,368
-41,600
-37% -$678K ﹤0.01% 1053
2025
Q2 		$1.71M Buy
113,968
+91,600
+410% +$1.36M ﹤0.01% 975
2025
Q1 		$361K Sell
22,368
-42,600
-66% -$886K ﹤0.01% 1171
2024
Q4 		$1.51M Buy
64,968
+12,200
+23% +$358K ﹤0.01% 1064
2024
Q3 		$1.5M Buy
52,768
+17,600
+50% +$490K ﹤0.01% 1116
2024
Q2 		$827K Sell
35,168
-25,800
-42% -$870K ﹤0.01% 1195
2024
Q1 		$2.31M Buy
+60,968
New +$1.77M ﹤0.01% 973

Other funds holding SYRE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TD Asset Management's SYRE Position: Q2 2026 in Review

TD Asset Management reduced its Spyre Therapeutics (SYRE) stake by 16% in Q2 2026, selling an estimated $1.56M and leaving 115,990 shares worth $10.3M. The position accounts for 0.01% of the portfolio, ranked #650.

TD Asset Management first reported a position in SYRE in Q1 2024 and has held it in 10 quarters since. 150 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • TD Asset Management held 115,990 shares of Spyre Therapeutics worth $10.3M as of Q2 2026.
  • TD Asset Management sold 21,400 Spyre Therapeutics shares in Q2 2026, an estimated $1.56M.
  • Spyre Therapeutics made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #650 holding.
  • TD Asset Management first reported a position in Spyre Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 150 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.